Martínez-de-la-Casa, José María
Marcos-Parra, María Teresa
Millá-Griñó, Elena
Laborda, Teresa
Giménez-Gomez, Rafael
Larrosa, José Manuel
Urcola, Aritz
Teus, Miguel Ángel
Perucho-Martínez, Susana
Funding for this research was provided by:
AbbVie
Article History
Received: 8 October 2023
Accepted: 22 February 2024
First Online: 24 February 2024
Competing interests
: José María Martínez-de-la-Casa has received funding as consultant from Allergan, Santen, Alcon, Pfizer, Novartis, Thea, B&L, Glaukos, AJL, and VISUfarma, research funding from Santen, Ivantis, Allergan, Pfizer, Glaukos, and Thea, and lecturer funding from Allergan, Santen, Alcon, Pfizer, Novartis, Thea, B&L, Glaukos, and ICare. Maria Teresa Marcos-Parra has received funding as consultant from AbbVie and Allergan. Elena Milla has received funding as consultant from AbbVie, Allergan, Santen, Brill, and Thea. Teresa Laborda has no interests to declare. Rafael Giménez Gómez has received funding as a lecturer from Abbvie, Santen and Brill. José Manuel Larrosa Carrera has received funding as consultant from AbbVie and Johnson&Johnson. Javier Aritz Urcola Carrera has received funding as consultant from AbbVie and Allergan. Miguel Ángel Teus has received funding as a lecturer from Alcon and funding as consultant from Allergan. Susana Perucho Martinez has received funding as a lecturer from AbbVie, Allergan, Visufarma and Thea.